ACS Journal Cancer

An interdisciplinary international journal of the American Cancer Society. Editor-in-Chief: Suresh S. Ramalingam, MD (@RamalingamMD)

[ACS Journal Cancer @JournalCancer]

Just released! The Annual Report to the Nation on the Status of Cancer shows that from 2019-2023, overall cancer death rates decreased largely due to fewer deaths from lung cancer.

See trends in new cancer cases and deaths: https://t.co/4McxEOgKSn

#CancerAnnualReport @OncoAlert

[ACS Journal Cancer @JournalCancer]

Tumor biology in #BreastCancer is important, but anatomic extent of disease still has a role in determining prognosis.

A recent study from @JenniferPlichta and @DukeSurgery investigators explains more: https://t.co/ExqqY2SZn8

@OncoAlert @DukeCancer CC: @oreganruth #BCSM

[ACS Journal Cancer @JournalCancer]

Working in #pedonc, #ayacancer, or a related field? Follow @PedAYAJournal for updates on our new #OpenAccess journal.

Hear from @billdahutmd on how the journal aims to support research momentum across pediatric & AYA oncology.

See more: https://t.co/QhFfZBYDhf

@OncoAlert

[ACS Journal Cancer @JournalCancer]

Which patients with metastatic APMS #ProstateCancer may benefit most from talazoparib + enzalutamide?

TALAPRO-3 findings highlight outcomes across HRR gene alterations. See our latest #CancerScope for more: https://t.co/ueGqnzyqNF

@OncoAlert

[ACS Journal Cancer @JournalCancer]

A new @AmericanCancer study led by Erika Rees-Punia PhD reveals physical activity after a cancer diagnosis is linked to lower healthcare costs among older survivors.

Learn more: https://t.co/TvYqGuwY8N

@OncoAlert @DrRobinYabroff @AlpaVPatel #ExerciseOncology #GeriOnc

[ACS Journal Cancer @JournalCancer]

As the use of CDK4/6 inhibitors in early-stage #BreastCancer grows, thoughtful patient selection matters.

A recent review explores how recurrence risk, side effects, treatment burden, and patient preferences can guide care.

🔗 https://t.co/lejcdP6EAv

@OncoAlert @adwilliams5

[Pediatric, Adolescent & Young Adult Cancer @PedAYAJournal]

Considering submitting your research to @PedAYAJournal? In this video, Dr. Nirali Shah discusses the types of manuscripts the journal is seeking.

Watch below or on YouTube: https://t.co/2R8zbfkBmt

View our Author Guidelines: https://t.co/mO7tE6B5D6

@OncoAlert #AYACSM #PedOnc

[ACS Journal Cancer @JournalCancer]

New in #CancerScope 📗 The RET inhibitor selpercatinib significantly improved EFS in comparison with a placebo for patients with early-stage RET-positive #NSCLC according to results of the LIBRETTO-432 trial.

See our coverage of the findings: https://t.co/ph3txnyvJX

@OncoAlert

[ACS Journal Cancer @JournalCancer]

#OpenAccess 🔓 Efficacy of a structured rehabilitation program for patients with terminal cancer: A multicenter randomized controlled trial

https://t.co/5RDgzCwFaN

@OncoAlert

[ACS Journal Cancer @JournalCancer]

The VOICES of Black Women Study is addressing critical research gaps in cancer risk & outcomes.

@Dr_LEMcCullough examines its impact in CancerSpeak & an editorial in CANCER.

📖 Read: https://t.co/iqjPObHobs
🎧 Listen: https://t.co/kAjMMdvL2s

@OncoAlert

[ACS Journal Cancer @JournalCancer]

Results of two late-breaking trials presented at #ASCO26 show that ivonescimab combined with chemotherapy improved overall survival, and sunvozertinib improved progression-free survival, for patients with #NSCLC.

Read our latest #CancerScope: https://t.co/an5LO6JJk9

@OncoAlert

[Vivek Subbiah, MD @VivekSubbiah]

⭐️The weight of the enemy: Tumor burden as a tumor‐agnostic prognostic marker and the limits of immunotherapy - Subbiah - 2026 - Cancer - Wiley Online Library @EladSharonMD @JournalCancer @ACSCAN @OncoAlert

https://t.co/116MqNYtRP

[ACS Journal Cancer @JournalCancer]

New from @MoffittNews @GuardantHealth researchers 💡

In IDH1+ aCCA, immunotx added to GemCis was assoc w/ inferior rwOS. Findings support obtaining ctDNA-based CGP before initiating 1L therapy & underscore the need for prospective studies.

https://t.co/OyNET8P61d

@OncoAlert

[ACS Journal Cancer @JournalCancer]

New editorial by Drs. Weam Almasaud & Ronda Lun of @DCNSNeuro 🧠 Increased risk of stroke after a new cancer diagnosis—Where are the knowledge gaps currently? https://t.co/R5A3ghQVDd

Accompanying article: https://t.co/LQCiw8gSXR

@OncoAlert #neuroonc

[ACS Journal Cancer @JournalCancer]

New & #OpenAccess 🔓 C-reactive protein kinetics may help assess early response and prognosis in biliary tract cancer treated with chemoimmunotherapy. However, these findings require prospective external validation in larger cohorts.

https://t.co/qYx8mMCOVI

@OncoAlert

[Wiley Clinical and Health @WileyHealth]

Revisit the 2025 @AmericanCancer report providing statistics on lobular breast cancer in the United States published in @JournalCancer: https://t.co/B2htN8TCDT

The article is also featured in Wiley's #BreastCancerAwarenessMonth collection: https://t.co/7VFmjXsjlW

#BCAM #BCSM 🩷

[ACS Journal Cancer @JournalCancer]

New #OpenAccess review article summarizes the current evidence supporting the use of #ProtonTherapy across major disease sites and discusses ongoing studies likely to further define the role of proton therapy in modern oncology.

https://t.co/9OasjAXdoN

@OncoAlert #RadOnc

[ACS Journal Cancer @JournalCancer]

Is IL-6 is predictive of benefit for olaparib alone or in combination with cediranib in patients with recurrent, persistent, or metastatic endometrial cancer?

See new work led by Andrew B. Nixon PhD, MBA of @DukeCancer: https://t.co/kuschqbjaJ

@OncoAlert #gyncsm

[ACS Journal Cancer @JournalCancer]

Cancer death rates declined every year from 2019 to 2023 largely due to fewer deaths from lung cancer. However, lung cancer remains the no. 1 cause of cancer deaths in the U.S.

Read the 2026 #CancerAnnualReport: https://t.co/AeBKukqpX1

@OncoAlert

[Wiley Clinical and Health @WileyHealth]

Discover the latest #BreastCancer research in our specially curated collection, including articles from @JournalCancer, @CACancerJournal, @CancerCytopath, @PedAYAJournal, @IntJCanc, @Wiley_CancerRep, @CancerMedicineJ, and more!

🔗➡️ https://t.co/UJ4G2eZUDX

#BCAM 💗🎗️

[Pediatric, Adolescent & Young Adult Cancer @PedAYAJournal]

It was so great connecting with the pediatric & AYA oncology community at #COGFall2026 in Chicago! 💜🧸

Thanks to everyone who joined our editorial meet-and-greets and shared enthusiasm for Pediatric, Adolescent & Young Adult Cancer.

Stay connected: https://t.co/VZdSzTTfj4